(Q38112660)

29 August 2017

title

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus (English)

1 reference

29 August 2017

0 references

Shawn Riser Taylor

1

1 reference

29 August 2017

Kira B Harris

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

6 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

33

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

984-999

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

29 August 2017

cites work

1 reference

21 January 2018

1 reference

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus

21 January 2018

1 reference

21 January 2018

1 reference

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors

21 January 2018

1 reference

THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN.

21 January 2018

1 reference

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

21 January 2018

1 reference

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

21 January 2018

1 reference

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein

21 January 2018

1 reference

GLUT1 deficiency and other glucose transporter diseases

21 January 2018

1 reference

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

Glucose transporters: structure, function and consequences of deficiency

21 January 2018

1 reference

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

Active sugar transport in health and disease

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

21 January 2018

1 reference

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1303

1 reference

29 August 2017

1 reference